What difference would it make having us on board or not? None. If sh had to vote on a 5c deal, how many would vote? If Hopper got a deal he sets the benchmark and gets it done whether retail and funds would agree or not.
At CHM he chose the sp-destructive way too and no deal was and is insight. CAR-T isn't the hottest kid on the block anymore. 7 auto CD19 CAR-Ts got approved but just 2 are getting used. About 300 comps working on allo CD19 CAR-Ts for all types of blood and skin cancers and a few, such as CHM, work on solid cancer attacking CAR-Ts. Those solid ones can't be done as allos yet, still using auto CAR-Ts. One treatment about US $500k, insurers are reluctant to pay for it. Hence big pharma reluctant to spend more on CAR-Ts if they can't make money from it. Different story if costs come down significantly but that is not on the horizon atm.
And Trump demanding lower costs won't help either. B-cell vax - varieties could be one way to tackle cancer simpler and a lot cheaper. Check point inhibitors such as Keytruda had some success, maybe it was a strategic mistake to priorities Azer-Cel over B-cell. When listening to Prof Dr Wiedermann and Dr Joshua Tobias they were and are convinced that the B-cell time is yet to come.
One can only hope that CF33 and B-cell will save the company if big pharma turns its back to CAR-Ts.
IMU Price at posting:
1.7¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)